Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis
Clinical Trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis
The study sponsor, Ra Pharma, is developing an investigational drug, zilucoplan, for treatment of people with gneralized myasthenia gravis, or gMG. gMG is caused when your immune system attacks part of your muscle and prevents the nerve signal from getting through. Zilucoplan is designed to prevent the immune system from attacking your muscles. The main purpose of this study is to test whether zilucoplan works and is safe for people with gMG.
Eligibility Criteria
- Inclusion Criteria: Have a documented history of generalized Myasthenia Gravis at the screening visit with documentation stating that you are positive for AChR. Exclusion Criteria: Have received treatment with rituximab within 12 months prior to Screening. Have an active or untreated thymoma, a history of thymectomy within the 12 months prior to the screening visit, or a history of malignancy unless deemed cured by adequate treatment and with no evidence of it reoccuring for greater than 12 months before the screening visit.
RESEARCH. INNOVATION. DISCOVERY.